Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S F Wolf

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Clinical Immunology (Orlando, Fla.)|September 10, 1999
Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory proteinH Swiniarski, K Sturmhoefel, K Lee, et al.
The Journal of Clinical Investigation|April 1, 1994
Interleukin 12 at the site of disease in tuberculosisM Zhang, M K Gately, E Wang, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|July 11, 2000
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responsesK Lee, W W Overwijk, M O'Toole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1992
Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cellsB Perussia, S H Chan, A D'Andrea, et al.
The Journal of Experimental Medicine|March 1, 1992
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSFM J Robertson, R J Soiffer, S F Wolf, et al.
European Journal of Immunology|July 13, 2001
Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunityA A Byrnes, X Ma, P Cuomo, et al.
International Immunology|July 1, 1995
Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cellsJ P Zou, N Yamamoto, T Fujii, et al.
Human Gene Therapy|December 1, 1994
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12L Zitvogel, H Tahara, Q Cai, et al.
The Journal of Experimental Medicine|October 1, 1993
Antitumor and antimetastatic activity of interleukin 12 against murine tumorsM J Brunda, L Luistro, R R Warrier, et al.
Infection and Immunity|May 29, 1998
Acute and chronic phases of Toxoplasma gondii infection in mice modulate the host immune responsesT D Nguyen, G Bigaignon, J Van Broeck, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Clinical Immunology (Orlando, Fla.)|September 10, 1999
Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory proteinH Swiniarski, K Sturmhoefel, K Lee, et al.
The Journal of Clinical Investigation|April 1, 1994
Interleukin 12 at the site of disease in tuberculosisM Zhang, M K Gately, E Wang, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|July 11, 2000
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responsesK Lee, W W Overwijk, M O'Toole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1992
Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cellsB Perussia, S H Chan, A D'Andrea, et al.
The Journal of Experimental Medicine|March 1, 1992
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSFM J Robertson, R J Soiffer, S F Wolf, et al.
European Journal of Immunology|July 13, 2001
Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunityA A Byrnes, X Ma, P Cuomo, et al.
International Immunology|July 1, 1995
Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cellsJ P Zou, N Yamamoto, T Fujii, et al.
Human Gene Therapy|December 1, 1994
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12L Zitvogel, H Tahara, Q Cai, et al.
The Journal of Experimental Medicine|October 1, 1993
Antitumor and antimetastatic activity of interleukin 12 against murine tumorsM J Brunda, L Luistro, R R Warrier, et al.
Infection and Immunity|May 29, 1998
Acute and chronic phases of Toxoplasma gondii infection in mice modulate the host immune responsesT D Nguyen, G Bigaignon, J Van Broeck, et al.
Pageof 8